首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer
【2h】

Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer

机译:在发芽糙米上生长的桑黄增加了KRAS突变结肠癌的西妥昔单抗敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colon cancer is one of the most common types of cancer, and it has recently become a leading cause of death worldwide. Among colon cancers, the v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated form is notorious for its non-druggable features. Cetuximab, a monoclonal antibody that binds to the epidermal growth factor receptor, has been introduced as an antitumor therapy; however, secondary resistance and side effects significantly limit its effective use in these cancers. In this study, we prepared Phellinuslinteus on germinated brown rice (PBR) extracts to increase the sensitivity of KRAS-mutated colon cancers to cetuximab. The combined treatment of PBR extract and cetuximab suppressed SW480 cell viability/proliferation, with the cells exhibiting altered cellular morphology and clonogenic potential. AnnexinV–fluorescein isothiocyanate/propidium iodide–stained flow cytometry and Western blotting were performed, and PBR extract combined with cetuximab treatment increased apoptosis of the SW480 cells and suppressed their KRAS protein expression. The potential of PBR as a synergistic anticancer agent was further investigated in a tumor-xenografted mouse model. Tumor growth was significantly suppressed with PBR extract and cetuximab co-treatment. In conclusion, PBR increased the sensitivity of KRAS-mutated colon cancer cells to cetuximab, which indicates the potential use of PBR as a medical food against colon cancer.
机译:结肠癌是最常见的癌症类型之一,最近已成为全球主要的死亡原因。在结肠癌中,v-ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变形式因其不易吸毒的特性而臭名昭著。西妥昔单抗是一种结合表皮生长因子受体的单克隆抗体,已被引入抗肿瘤治疗。但是,继发性耐药和副作用严重限制了其在这些癌症中的有效使用。在这项研究中,我们在发芽的糙米(PBR)提取物中制备了桑黄,以增加KRAS突变的结肠癌对西妥昔单抗的敏感性。 PBR提取物和西妥昔单抗的联合处理可抑制SW480细胞的活力/增殖,并使细胞表现出改变的细胞形态和克隆形成潜力。进行AnnexinV-异硫氰酸荧光素/碘化丙啶染色-流式细胞仪和Western blotting,PBR提取物与西妥昔单抗联合治疗可增加SW480细胞凋亡并抑制其KRAS蛋白表达。在肿瘤异种移植小鼠模型中进一步研究了PBR作为协同抗癌剂的潜力。 PBR提取物和西妥昔单抗共同治疗可显着抑制肿瘤生长。总之,PBR增加了KRAS突变的结肠癌细胞对西妥昔单抗的敏感性,这表明PBR作为抗结肠癌的医疗食品的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号